MiMedx Group Inc. announced it has entered into an exclusive U.S. distribution agreement with Regen Lab USA LLC for RegenKit®-Wound Gel. The agreement enables MiMedx to distribute RegenKit®-Wound Gel, an autologous platelet-rich plasma and thrombin serum wound gel, in the United States. The product is FDA-approved and covered nationally by CMS and LCD for the treatment of diabetic chronic wounds under HCPCS code G0465.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MiMedx Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9615994-en) on December 22, 2025, and is solely responsible for the information contained therein.